自己免疫疾患用薬の世界市場2016-2020

◆英語タイトル:Global Autoimmune Drugs Market 2016-2020
◆商品コード:IRTNTR9055
◆発行会社(調査会社):Technavio
◆発行日:2016年3月18日
◆ページ数:137
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名利用)USD2,500 ⇒換算¥252,500見積依頼/購入/質問フォーム
Five User(~5名利用)USD3,000 ⇒換算¥303,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,000 ⇒換算¥404,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※レポート購入後、該当レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。Technavio社の概要及び新刊レポートはこちらでご確認いただけます。



当調査レポートでは、自己免疫疾患用薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、疾患概要、自己免疫疾患用薬の世界市場規模及び予測、種類別分析、剤形別分析、作用機序別分析、薬剤種類別分析、地域別分析/市場規模、市場の成長要因、市場の課題、市場動向、競争状況などの情報をお届けいたします。
【レポートの概要】

About Autoimmune Diseases Drugs

Autoimmune diseases are immunological disorders that occur when the immune system attacks and destroys healthy tissues in the body rather than foreign bodies, causing significant pain, inflammation, and organ damage. These diseases can affect the nervous system, cardiovascular system, and musculoskeletal system or individual organs, including the skin, lungs, kidneys, glands, and joints.
Autoimmune diseases occur due to genetic, infectious, or environmental factors. There are over 80 autoimmune diseases, including AS, IBD (CD and UC), MS, RA, SLE, and PsA. DMARDs, NSAIDs, corticosteroids, analgesics, and immunosuppressants are the major drug classes used to treat autoimmune diseases.

Technavio’s analysts forecast the global autoimmune diseases drugs market to grow at a CAGR of 5.57% during the period 2016-2020.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global autoimmune diseases drugs market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded, generic, and off-label drugs used for the treatment of autoimmune diseases.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio’s report, Global Autoimmune Diseases Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• AbbVie Inc.
• Amgen Inc.
• Biogen
• F. Hoffmann-La Roche
• Johnson & Johnson Private Limited
• Pfizer Inc.

[Other prominent vendors]
• Ablynx
• AB Science
• Acorda Therapeutics
• Alder BioPharmaceuticals
• Antares Pharma
• Astellas Pharma
• AstraZeneca
• Baxter
• Boehringer Ingelheim
• Can-Fite BioPharma
• Celgene
• Celltrion
• ChemoCentryx
• Coherus BioSciences
• Daiichi Sankyo
• Eisai
• Eli Lilly
• Gilead Sciences
• GSK
• Hospira
• Idera Pharmaceuticals
• Immunomedics
• ImmuPharma
• Incyte
• Invion
• KaloBios Pharmaceuticals
• Lexicon Pharmaceuticals
• Merck
• MedImmune
• Morphotek
• Novo Nordisk
• Novartis
• Opexa Therapeutics
• Principia Biopharma
• Regeneron Pharmaceuticals
• Sandoz
• Sanofi
• Santarus
• Takeda Pharmaceuticals
• UCB
• Vaccinex
• Vertex Pharmaceuticals
• Vitae Pharmaceuticals

[Market driver]
• Promising pipeline
• For a full, detailed list, view our report

[Market challenge]
• Loss of patent exclusivity of branded therapies
• For a full, detailed list, view our report

[Market trend]
• Increase in public awareness programs
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

※You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【レポートの目次】

PART 01: Executive summary
• Highlights

PART 02: Scope of the report
• Market overview
• Top-vendor offerings
• Assumptions

PART 03: Market research methodology
• Research methodology
• Economic indicators

PART 04: Introduction
• Key market highlights

PART 05: Disease overview
• Understanding the disease
• Etiology
• Signs and symptoms
• Diagnosis
• Management
• Economic burden
• Epidemiology

PART 06: Pipeline portfolio

PART 07: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis

PART 08: Market segmentation by type of disease
• RA
• MS
• PsA
• IBD
• AS
• SLE
• Global RA drugs market
• Clinical trials for RA
• Global MS drugs market
• Global PsA drugs market
• Global IBD drugs market
• Global AS drugs market
• Global SLE drugs market

PART 09: Market segmentation by mechanism of action
• TNF inhibitors
• IL-1 blockers
• COX inhibitors
• PDE4 inhibitors
• Others

PART 10: Market segmentation by drug class
• DMARDs
• NSAIDs
• Corticosteroids
• Analgesics
• Immunosuppressants
• Others

PART 11: Market segmentation by type of molecule
• Biologics
• Small molecules

PART 12: Market segmentation by ROA
• Oral
• Parenteral
• Topical

PART 13: Market segmentation by dosage form
• Solid
• Liquid
• Semi-solid

PART 14: Geographical segmentation
• Autoimmune diseases drugs market in the Americas
• Autoimmune diseases drugs market in US
• Autoimmune diseases drugs market in EMEA
• Autoimmune diseases drugs market in APAC
• Autoimmune diseases drugs market in Japan
• Autoimmune diseases drugs market in China

PART 15: Market drivers
• Rising prevalence of autoimmune diseases
• Growing older population
• Dominance of biologics
• Unmet medical needs
• Promising pipeline

PART 16: Impact of drivers

PART 17: Market challenges
• Increasing cost of biologics
• Loss of patent exclusivity of branded therapies
• Complex nature of autoimmune diseases
• Preference for CAMs
• Adverse effects

PART 18: Impact of drivers and challenges

PART 19: Market trends
• Emergence of biosimilars
• Patient assistance programs
• Increase in public awareness programs
• Strategic alliances
• Popularity of off-label and traditional treatment options

PART 20: Vendor landscape
• Competitive scenario
• Market analysis 2015
• AbbVie
• Johnson & Johnson
• Biogen
• Amgen
• Pfizer
• F. Hoffmann-La Roche
• Other prominent vendors

PART 21: Appendix
• List of abbreviations

PART 22: Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: Etiology of autoimmune diseases
Exhibit 03: Signs and symptoms of autoimmune diseases
Exhibit 04: Diagnostic methods for autoimmune diseases
Exhibit 05: Non-pharmacological therapies used for autoimmune diseases
Exhibit 06: Pharmacotherapy therapies used for autoimmune diseases
Exhibit 07: Top drugs for autoimmune diseases
Exhibit 08: Average annual treatment costs of RA in US and Europe 2014 ($ billions)
Exhibit 09: Average annual treatment costs of MS across countries 2014 ($ billions)
Exhibit 10: Average annual treatment costs of PsA across countries 2014 ($ billions)
Exhibit 11: Prevalence and incidence of SLE
Exhibit 12: Pipeline molecules for RA
Exhibit 13: Pipeline molecules for MS
Exhibit 14: Pipeline molecules for PsA
Exhibit 15: Pipeline molecules for CD
Exhibit 16: Pipeline molecules for UC
Exhibit 17: Pipeline molecules for SLE
Exhibit 18: Global autoimmune diseases drugs market 2015-2020 ($ billions)
Exhibit 19: Five forces analysis
Exhibit 20: Global autoimmune diseases drugs market segmentation by type of disease
Exhibit 21: Global autoimmune diseases drugs market by type of disease 2015
Exhibit 22: Global autoimmune diseases drugs market: YoY revenue and growth based on autoimmune diseases 2015-2020
Exhibit 23: Global RA drugs market 2015-2020 ($ billions)
Exhibit 24: Global RA drugs market by drug class 2015
Exhibit 25: Top-vendor offerings for global RA drugs market
Exhibit 26: RA clinical trial by Phase 2015
Exhibit 27: RA clinical trial by status 2015
Exhibit 28: Drivers and challenges of global RA drugs market
Exhibit 29: Global MS drugs market 2015-2020 ($ billions)
Exhibit 30: Global MS drugs market by molecule type 2015
Exhibit 31: Top-vendor offerings for global MS drugs market
Exhibit 32: Drivers and challenges of global MS drugs market
Exhibit 33: Global PsA drugs market 2015-2020 ($ billions)
Exhibit 34: Global PsA drugs market segmentation by MOA 2015
Exhibit 35: Top-vendor offerings for global PsA drugs market
Exhibit 36: Drivers and challenges of global PsA drugs market
Exhibit 37: Global IBD drugs market 2015-2020 ($ billions)
Exhibit 38: Global IBD drugs market by type of disease 2015
Exhibit 39: Global IBD drugs market by drug class 2015
Exhibit 40: Top-vendor offerings for global IBD drugs market
Exhibit 41: Drivers and challenges of global IBD drugs market
Exhibit 42: Global AS drugs market 2015-2020 ($ billions)
Exhibit 43: Global AS drugs market by MOA 2015
Exhibit 44: Top-vendor offerings for global AS drugs market
Exhibit 45: Drivers and challenges of global AS drugs market
Exhibit 46: Global SLE drugs market 2015-2020 ($ billions)
Exhibit 47: Drivers and challenges of global SLE drugs market
Exhibit 48: Global autoimmune diseases drugs market segmentation by MOA
Exhibit 49: Average percentage of patients receiving TNF inhibitors 2010 and 2015
Exhibit 50: Global autoimmune diseases drugs market share by MOA 2015
Exhibit 51: Global autoimmune diseases drugs market segmentation by drug class
Exhibit 52: Examples of non-biologic DMARDs and biologic DMARDs for autoimmune diseases
Exhibit 53: NSAIDs used to treat autoimmune diseases
Exhibit 54: Global autoimmune diseases drugs market by drug class 2015
Exhibit 55: Global autoimmune diseases drugs market segmentation by type of molecule
Exhibit 56: Global autoimmune diseases biologics market 2015-2020 ($ billions)
Exhibit 57: Global autoimmune diseases small molecules market 2015-2020 ($ billions)
Exhibit 58: Global autoimmune diseases drugs market by type of molecules 2015
Exhibit 59: Global autoimmune diseases drugs market segmentation by ROA
Exhibit 60: Global autoimmune diseases drugs market segmentation by ROA 2015
Exhibit 61: Global autoimmune diseases drugs market segmentation by dosage form
Exhibit 62: Global autoimmune disease drugs market segmentation by dosage form 2015
Exhibit 63: Global autoimmune diseases drugs market segmentation by geography 2015
Exhibit 64: Global autoimmune diseases drugs market revenue by geography 2015-2020 ($ billions)
Exhibit 65: Autoimmune diseases drugs market in the Americas 2015-2020 ($ billions)
Exhibit 66: Autoimmune diseases drugs market in America by country 2015
Exhibit 67: Autoimmune diseases drugs market in US 2015-2020 ($ billions)
Exhibit 68: Drivers and challenges for autoimmune diseases drugs market in the US
Exhibit 69: Autoimmune diseases drugs market in EMEA 2015-2020 ($ billions)
Exhibit 70: Autoimmune diseases drugs market in APAC 2015-2020 ($ billions)
Exhibit 71: Autoimmune diseases drugs market in Japan 2015-2020 ($ billions)
Exhibit 72: Drivers and challenges for autoimmune diseases drugs market in Japan
Exhibit 73: Autoimmune diseases drugs market in China 2015-2020 ($ billions)
Exhibit 74: Global autoimmune diseases drugs market YoY revenue and growth based on geography 2015-2020 ($ billions)
Exhibit 75: Population aged 60 years and over ($ millions)
Exhibit 76: Biologics approval timeline by US FDA
Exhibit 77: Some pipeline molecules under phases of development for autoimmune diseases
Exhibit 78: Impact of drivers
Exhibit 79: Average annual treatment cost of adalimumab, etanercept, and infliximab 2014 ($ millions)
Exhibit 80: Approval and patent expiries of top selling biologics
Exhibit 81: CAM therapies for autoimmune diseases
Exhibit 82: Usage of CAM therapies among individuals in US 2014
Exhibit 83: Adverse effects associated with autoimmune disease therapies
Exhibit 84: Impact of drivers and challenges
Exhibit 85: Patient assistance programs for autoimmune diseases drugs
Exhibit 86: Revenue share of major companies for autoimmune diseases 2015
Exhibit 87: YoY Sales comparison of top drugs 2013-2015 ($ billions)
Exhibit 88: AbbVie: Product segmentation by revenue 20150
Exhibit 89: AbbVie: YoY growth rate and revenue of HUMIRA 2013-2015 ($ billions)
Exhibit 90: AbbVie: YoY growth rate and revenue of HUMIRA in US 2013-2015 ($ billions)
Exhibit 91: AbbVie: YoY growth rate and revenue of HUMIRA in ROW 2013-2015 ($ billions)
Exhibit 92: Sales of HUMIRA in major markets
Exhibit 93: AbbVie: Key takeaways
Exhibit 94: Johnson & Johnson: Segmentation of key autoimmune diseases drugs 2014
Exhibit 95: Johnson & Johnson: YoY growth rate and revenue of Remicade 2013-2014 ($ billions)
Exhibit 96: Johnson & Johnson: YoY growth rate and revenue of Remicade in US 2013-2015 ($ billions)
Exhibit 97: Johnson & Johnson: YoY growth rate and revenue of Remicade in ROW 2013-2015 ($ billions)
Exhibit 98: Johnson & Johnson: YoY growth rate and revenue of Stelara 2013-2015 ($ billions)
Exhibit 99: Johnson & Johnson: YoY growth rate and revenue of Stelara in US 2013-2015 ($ billions)
Exhibit 100: Johnson & Johnson: YoY growth rate and revenue of Stelara in ROW 2013-2015 ($ millions)
Exhibit 101: Johnson & Johnson: YoY growth rate and revenue of Simponi/Simponi Aria 2013-2015 ($ billions)
Exhibit 102: Johnson & Johnson: YoY growth rate and revenue of Simponi/Simponi Aria in US 2013-2015 ($ millions)
Exhibit 103: Johnson & Johnson: YoY growth rate and revenue of Simponi/Simponi Aria in ROW 2013-2015 ($ millions)
Exhibit 104: Johnson & Johnson: Key takeaways
Exhibit 105: Biogen: Product segmentation of key autoimmune diseases drugs by revenue 2015
Exhibit 106: Top selling autoimmune diseases drugs
Exhibit 107: Biogen: YoY growth rate and revenue of Tecfidera 2013-2015 ($ billions)
Exhibit 108: Biogen: YoY growth rate and revenue of Avonex 2013-2015 ($ billions)
Exhibit 109: Biogen: YoY growth rate and revenue of Tysabri 2013-2015 ($ billions)
Exhibit 110: Biogen: YoY revenue of Plegridy 2014-2015 ($ millions)
Exhibit 111: Biogen: YoY growth rate and revenue of Fampyra 2013-2015 ($ millions)
Exhibit 112: Biogen: Key takeaways
Exhibit 113: Amgen: YoY growth rate and revenue of Enbrel in US and Canada 2013-2015 ($ billions)
Exhibit 114: Amgen: YoY growth rate and revenue of Enbrel in US 2013-2015 ($ billions)
Exhibit 115: Amgen: YoY growth rate and revenue of Enbrel in Canada 2013-2015 ($ millions)
Exhibit 116: Amgen: Key takeaways
Exhibit 117: Pfizer: Autoimmune diseases drugs product segmentation by revenue 2014
Exhibit 118: Top selling autoimmune diseases drugs
Exhibit 119: Pfizer: YoY growth rate and revenue of Enbrel (outside US and Canada) 2013-2015 ($ billions)
Exhibit 120: Pfizer: YoY growth rate and revenue of Celebrex 2013-2015 ($ billions)
Exhibit 121: Pfizer: YoY growth rate and revenue of Xeljanz 2012-2014 ($ millions)
Exhibit 122: Pfizer: Key takeaways
Exhibit 123: Top selling autoimmune diseases drugs
Exhibit 124: F. Hoffmann-La Roche: YoY growth rate and revenue of Actemra/RoActemra 2013-2015 ($ billions)
Exhibit 125: F. Hoffmann-La Roche: Actemra/RoActemra geographic segmentation by revenue 20155
Exhibit 126: F. Hoffmann-La Roche: YoY growth rate and revenue of MabThera/Rituxan (oncology and immunology indications) 2013-2015 ($ billions)
Exhibit 127: F. Hoffmann-La Roche: YoY growth rate and revenue of MabThera/Rituxan (immunology indications only) 2013-2015 ($ billions)
Exhibit 128: F. Hoffmann-La Roche: Geographic segmentation of MabThera/Rituxan by revenue 2015
Exhibit 129: F. Hoffmann-La Roche: Key takeaways



【掲載企業】

AbbVie Inc., Amgen Inc., Biogen, F. Hoffmann-La Roche, Johnson & Johnson Private Limited, Pfizer Inc, Ablynx, AB Science, Acorda Therapeutics, Alder BioPharmaceuticals, Antares Pharma, Astellas Pharma, AstraZeneca, Baxter, Boehringer Ingelheim, Can-Fite BioPharma, Celgene, Celltrion, ChemoCentryx, Coherus BioSciences, Daiichi Sankyo, Eisai, Eli Lilly, Gilead Sciences, GSK, Hospira, Idera Pharmaceuticals, Immunomedics, ImmuPharma, Incyte, Invion, KaloBios Pharmaceuticals, Lexicon Pharmaceuticals, Merck, MedImmune, Morphotek, Novo Nordisk, Novartis, Opexa Therapeutics, Principia Biopharma, Regeneron Pharmaceuticals, Sandoz, Sanofi, Santarus, Takeda Pharmaceuticals, UCB, Vaccinex, Vertex Pharmaceuticals, Vitae Pharmaceuticals.


【レポートのキーワード】

自己免疫疾患、治療薬、AS、多発性硬化症(MS)、全身性エリテマトーデス(SLE)、乾癬性関節炎(PsA)、炎症性腸疾患(IBD)、医薬品

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

【免責事項】
※当レポート上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当レポートに記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当レポート上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチ(株)はその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチ(株)が翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

★調査レポート[自己免疫疾患用薬の世界市場2016-2020]についてメールでお問い合わせはこちら


※世界の市場調査資料 総合販売サイトMarketReport.jpはH&Iグローバルリサーチ株式会社が運営しております。海外進出、グローバル事業戦略策定、新規事業機会の発掘、競合他社の動向把握などに必要な情報やインサイトをお客様にご提供しております。H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。
※当サイトでは2016年09月24日現在 206,469 件の調査レポートを取り扱っております。当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。

◆H&Iグローバルリサーチのお客様(例)◆